Immunotherapy with anti-programmed cell death-ligand 1 (PD-L1) agents is a new treatment option for tumors that do not respond to classical treatment methods and is widely used for the treatment of malignant melanoma, lung carcinoma, renal cell carcinoma, and lymphoma [12-14]. Here, CD274 is linked to hereditary clear cell renal cell carcinoma.